Eisai

Eisai is a pharmaceuticals company best known for medicines in neurology and oncology, which already tells you the kind of discipline it demands. By our assessment, its strength is research depth: this is a drug-maker that has built a reputation in hard therapeutic areas where development is slow and the standards are unforgiving. The downside is that pharmaceuticals like this are exposed to patent pressure, trial risk and the long wait before a product proves itself in the market. In practice, Eisai sits in the world of labs, clinical studies, regulators and prescription medicines rather than consumer-facing healthcare. Compared with broad pharmaceutical conglomerates, it is more focused and less sprawling, which is good if you value specialization and less good if you want diversification. The catalogue marks it for Japan, and that fits the company’s identity in the market. It is a serious research-driven name, not a consumer brand, and that is the level at which it should be judged.